M&A - BML Investment Partners, L.P.

Form Type: SCHEDULE 13D

Filing Date: 2025-06-16

Corporate Action: Merger

Type: Update

Accession Number: 000137360425000088

Filing Summary: BML Investment Partners, L.P. filed this Schedule 13D to report their ownership of 4,030,102 shares of Ikena Oncology, Inc., which represents approximately 8.35% of the company's common stock. The filing includes the identification of Braden M. Leonard, who is both the managing member of BML Capital Management, LLC and the sole general partner of BML Investment Partners, L.P. The document indicates that the shares were acquired for investment purposes using $6.7 million of working capital. Notably, the filing reveals that BML Investment Partners has sent a letter to the board of Ikena Oncology, stating their opposition to the proposed merger with Inmagene, arguing that it is not in the best interests of shareholders. The reporting entity has indicated no current plans for further action other than expressing their dissent regarding the merger, while also reserving the right to evaluate their investment over time.